Showing 7811-7820 of 8879 results for "".
- OM1 Launches HS Dataset to Expand Use of Real-World Evidence in Dermatologyhttps://practicaldermatology.com/news/om1-launches-hs-dataset-to-expand-real-world-evidence-in-dermatology/2462019/
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- POCN Launches AD Center of Excellencehttps://practicaldermatology.com/news/pocn-launches-ad-center-of-excellence/2461965/
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- US FDA Grants Breakthrough Device Designation to Marpe's Dermatology Screening Systemhttps://practicaldermatology.com/news/us-fda-grants-breakthrough-device-designation-to-marpes-dermatology-screening-system/2461900/The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Marpe Technologies full-body Dermatology Screening System. The Marpe System is designed to acquire and analyze total body images to support the identification of malignant and pre-malignant lesions,
- A Clinician's Guide to Alopecia: Diagnosis, Treatment, and Preventionhttps://practicaldermatology.com/news/a-clinicians-guide-to-alopecia-diagnosis-treatment-and-prevention/2461898/Hair loss, also known as alopecia, is a prevalent condition that affects people across every demographic.1 Unlike other skin issues that may remain unnoticed for extended periods, hair loss is often immediately apparent to the patient. Recently, alopecia has gained significant media at
- Merck, Moderna Initiate Phase 3 Study of V940-KEYTRUDA Combo for Adjuvant Treatment of Resected High-risk Melanomahttps://practicaldermatology.com/news/merck-moderna-initiate-phase-3-study-of-v940-mrna-4157-in-combination-with-keytruda-for-adjuvant-treatment-of-patients-with-resected-high-risk-melanoma/2461890/Merck today announced th
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patient
- Study: DermaSensor Correctly Identifies 96.2% of Melanomas in Senior Citizenshttps://practicaldermatology.com/news/study-dermasensor-correctly-identifies-962-of-melanomas-in-senior-citizens/2461863/DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting. The sensitivity of the DermaSensor device for melanoma